Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters
Lundbeck's development pipelin
(Thomson Reuters ONE) - H. Lundbeck A/S strengthens its pipeline of pharmaceuticals inclinical development by initiating phase I clinical studies with Lu02-750 in order to investigate safety, tolerability and thepharmacokinetic profile of the drug in humans. The placebo-controlledstudy is expected to enrol around 100 healthy individuals.Lu 02-750 is a dopaminergic agent acting on brain areas affected inParkinson's disease. In animal models, the compound has demonstratedvery convincing effects as compared to conventional treatments.Expectations are that the compound can offer Parkinson's patients anew and higher level of disease control."Focus at Lundbeck Research is to discover new innovative treatmentsthat address unmet needs and offer clear benefits to the patients andwe believe that Lu 02-750 has the potential to improve the treatmentand life quality of patients suffering from Parkinson's disease",says Executive Vice President Peter Høngaard Andersen, Head ofResearch at Lundbeck and continues: "Lundbeck is actively pursuingexternal technologies and collaborations and Lu 02-750 has beendiscovered in close collaboration with Professor Håkan Wikström,Groningen University and Axon Biochemicals B.V."About Parkinson's diseaseParkinson's disease is an age-related degenerative disorder of thebrain. Symptoms can include tremor, stiffness, slowness of movementand impaired balance. An estimated four million people worldwidesuffer from the disease, which usually affects people over the age of60.Lundbeck contactsInvestors: Media:Jacob Tolstrup Mads KronborgDirector, IR & Communication Media Relations+45 36 43 30 79 +45 36 43 28 51Palle Holm Olesen Kasper RiisHead of Investor Relations Media Relations+45 36 43 24 26 +45 36 43 28 33Magnus Thorstholm JensenInvestor Relations Officer+45 36 43 38 16About LundbeckH. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an internationalpharmaceutical company highly committed to improve the quality oflife for people suffering from central nervous system (CNS)disorders. For this purpose Lundbeck is engaged in the research anddevelopment, production, marketing and sale of pharmaceuticals acrossthe world, targeted at disorders like depression and anxiety,schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson'sdiseases.Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark,and employs today over 5,500 people worldwide. Lundbeck is one of theworld's leading pharmaceutical companies working with CNS disorders.In 2008, the company's revenue was DKK 11.3 billion (approximatelyEUR 1.5 billion or USD 2.2 billion). For more information, pleasevisit www.lundbeck.com.http://hugin.info/130085/R/1351468/326639.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 30.10.2009 - 10:00 Uhr
Sprache: Deutsch
News-ID 7679
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 329 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters
Lundbeck's development pipelin"
steht unter der journalistisch-redaktionellen Verantwortung von
H. Lundbeck A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
